Tower Research Capital (TRC)’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Tower Research Capital (TRC)’s Portfolio ENZN Stock Details ENZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,177	Closed	-$1K	–	5623
2015 Q4	$1K	Buy	+2,177	New	+$1.73K	﹤0.01%	4327
2015 Q3	–	Sell	-100	Closed	–	–	5406
2015 Q2	$0	Sell	100 -9,419	-99%	-$12K	﹤0.01%	5525
2015 Q1	$10K	Sell	9,519 -12,017	-56%	-$12.4K	﹤0.01%	2832
2014 Q4	$23K	Sell	21,536 -12,612	-37%	-$13.2K	﹤0.01%	1519
2014 Q3	$37K	Buy	34,148 +9,834	+40%	+$12.1K	﹤0.01%	1806
2014 Q2	$25K	Buy	24,314 +7,468	+44%	+$7.12K	﹤0.01%	1723
2014 Q1	$17K	Buy	+16,846	New	+$17.4K	﹤0.01%	2087

Other funds holding ENZN

Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Tower Research Capital (TRC)'s ENZN Position: Q1 2016 in Review

Tower Research Capital (TRC) sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q1 2016, closing a stake of 2,177 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in ENZN in Q1 2014 and held it in 7 quarters. The position peaked at $37K in Q3 2014. 40 funds tracked by Wall St. Rank hold ENZN as of Q1 2016.

Tower Research Capital (TRC) reported no remaining ENZON PHARMACEUTICALS INC position as of Q1 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 2,177 ENZON PHARMACEUTICALS INC shares in Q1 2016, an estimated $1K.
Tower Research Capital (TRC) first reported a position in ENZON PHARMACEUTICALS INC in Q1 2014 and held it in 7 quarters.
Tower Research Capital (TRC)'s ENZON PHARMACEUTICALS INC position peaked at $37K in Q3 2014.
40 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q1 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2016, filed 16 May 2016.